Hearing Disorders and DeafnessSEQUOIANCT07740070
Cognitive Processing of Natural Sequences in Humans and Artificial Intelligence (AI)
An observational study of Hearing Disorders and Deafness, run by Institut Pasteur.
Trial summary
The goal of this study is to identify electrical patterns in the cortex that enable the generation of predictions in natural auditory sequences such as speech and music. Between 500 and 700 participants in total (250 to 350 normally hearing participants (including 60 to 120 participants from West Africa and 60 to 120… Read more about this study
- Who is it for?
- Ages 18 to 85 yearsHealthy volunteers can take part
- Conditions the study is for
- Hearing Disorders and Deafness
- How many people
- 700 participants
- Where
- No sites listed yet
- Study dates
- Sep 2026to Nov 2033
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Hearing participants will be recruited from the general population in the Paris region. We will also recruit participants with hearing impairment through ENT clinics, in hearing aid dispensing centers. Finally, we will specifically recruit participants residing in Paris and of West African origin to examine differences related to cultural experience.
Who may be able to join
- For hearing participants:
- Average pure-tone thresholds ≤ 20 dB HL
- For participants with hearing loss:
- Average pure-tone thresholds > 20 dB HL
- For participants of West African origin:
- Average pure-tone thresholds ≤ 20 dB HL
- Declare that both parents are of West African origin, either by their own birth or by the birth of both of their parents.
Who cannot join
- No known neurological or audiological disorders
- Participants under legal guardianship (tutelle, curatelle)
- Participants deprived of legal liberty by judicial or administrative decision
About this study
Official title: SEQUOIA : Cognitive Processing of Natural Sequences in Humans and Artificial Intelligence (AI)
The goal of this study is to identify electrical patterns in the cortex that enable the generation of predictions in natural auditory sequences such as speech and music.
Between 500 and 700 participants in total (250 to 350 normally hearing participants (including 60 to 120 participants from West Africa and 60 to 120 participants from Western Europe) and 250 to 350 participants with hearing loss (no restrictions on origin)).
Participants will listen to naturally recorded music and speech via headphones. They will be asked to rate these stimuli on a scale from 0 to 10 in terms of pleasure and comprehension, using a keyboard and mouse or voice input. Additionally, they will be required to sing or produce novel/improvised vocal responses using high-fidelity microphones. This entire procedure will be conducted under electroencephalography (EEG) to record neuronal responses throughout the process.
- Conditions
- Hearing Disorders and Deafness
- Medical subject headings
- Hearing Disorders, Deafness
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Normal hearing participants from West Africa | Not described | |
| Normal hearing participants from Western Europe | Not described | |
| Participants with hearing loss | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Correlation between neural recordings and IA models
To identify electrical patterns in cortex which generates predictions in natural auditory sequences (such as speak and music).
Measured: Day 1
Secondary outcomes (4)
Compare predictions generated across different cultural contexts
specifically, comparing West African and Western European communities in Paris
Measured: Day 1
Compare predictions for identical stimuli across repeated sessions to establish a link between processing and successful memorization/retention.
Measured: From enrollement to visit 2 (10 days)
Compare predictions generated between hearing individuals and those with hearing impairments.
Measured: Day 2
Correlate predictive measures with responses to autism symptom questionnaires across the various experiments.
Measured: Day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Jul 2026
- Study startSep 2026 (estimated)
- Primary completionNov 2030 (estimated)
- Study completionNov 2033 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hearing Disorders and DeafnessStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 700 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Institut Pasteur
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- IHU reConnect
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07740070
- Sponsor's protocol ID
- 2024-102 SEQUOIA
- Other IDs
- 2025-A00021-48
- Acronym
- SEQUOIA
- Status last verified
- Jun 2026
- First submitted
- 16 Jun 2026
- Last updated
- 31 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 31 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- SEQUOIA : Cognitive Processing of Natural Sequences in Humans and Artificial Intelligence (AI)
- ClinicalTrials.gov ID
- NCT07740070
- Acronym / sponsor ID
- SEQUOIA / 2024-102 SEQUOIA
- Conditions
- Hearing Disorders and Deafness
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 700 participants (estimated)
- Lead sponsor
- Institut PasteurIndustry (pharma, biotech, devices)
- Collaborators
- IHU reConnect
- Study start
- Sep 2026 (estimated)
- Primary completion
- Nov 2030 (estimated)
- Study completion
- Nov 2033 (estimated)
- First posted
- 31 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this study is to identify electrical patterns in the cortex that enable the generation of predictions in natural auditory sequences such as speech and music.
Between 500 and 700 participants in total (250 to 350 normally hearing participants (including 60 to 120 participants from West Africa and 60 to 120 participants from Western Europe) and 250 to 350 participants with hearing loss (no restrictions on origin)).
Participants will listen to naturally recorded music and speech via headphones. They will be asked to rate these stimuli on a scale from 0 to 10 in terms of pleasure and comprehension, using a keyboard and mouse or voice input. Additionally, they will be required to sing or produce novel/improvised vocal responses using high-fidelity microphones. This entire procedure will be conducted under electroencephalography (EEG) to record neuronal responses throughout the process.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Normal hearing participants from West Africa | – | – |
| Normal hearing participants from Western Europe | – | – |
| Participants with hearing loss | – | – |
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Hearing participants will be recruited from the general population in the Paris region. We will also recruit participants with hearing impairment through ENT clinics, in hearing aid dispensing centers. Finally, we will specifically recruit participants residing in Paris and of West African origin to examine differences related to cultural experience.
Key inclusion criteria (7 listed)
- Average pure-tone thresholds ≤ 20 dB HL
- Average pure-tone thresholds > 20 dB HL
- Average pure-tone thresholds ≤ 20 dB HL
- Declare that both parents are of West African origin, either by their own birth or by the birth of both of their parents.
Key exclusion criteria (3 listed)
- No known neurological or audiological disorders
- Participants under legal guardianship (tutelle, curatelle)
- Participants deprived of legal liberty by judicial or administrative decision
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Correlation between neural recordings and IA models
Time frame: Day 1
To identify electrical patterns in cortex which generates predictions in natural auditory sequences (such as speak and music).
4 secondary outcomes
Compare predictions generated across different cultural contexts
Time frame: Day 1
Compare predictions for identical stimuli across repeated sessions to establish a link between processing and successful memorization/retention.
Time frame: From enrollement to visit 2 (10 days)
Compare predictions generated between hearing individuals and those with hearing impairments.
Time frame: Day 2
Correlate predictive measures with responses to autism symptom questionnaires across the various experiments.
Time frame: Day 1
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Jul 2026.
Related trials for Hearing Disorders and Deafness
Not yet recruiting
Effect of a Totally Implantable Cochlear Implant on Tinnitus Severity in Adults With Preoperative Tinnitus
Sensorineural Hearing Loss, Tinnitus
Enrolling by invitation
Self-monitoring of Hearing Aids Using Artificial Intelligence
Hearing Loss
Enrolling by invitationObservational study
Comparing an AI-driven Hearing Test With the Standard Hearing Test in Adults With Hearing Loss and Tinnitus
Sensorineural Hearing Loss, Tinnitus
Not yet recruitingPhase 1/2
A Study Testing the Safety and Possible Benefits of an Ear Injection of a New Compound, Paliroden, in People With Type 2 Diabetes Who Have Difficulty Understanding Speech in Noisy Situations
Cochlear Synaptopathy
Recruiting
Assessing Pharmacy Technician Educational Training for the Provision of Over-the-Counter Hearing Aids in Rural Alabama and Mississippi Pharmacies
Bilateral Hearing Loss, Health Services Research
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Hearing Disorders and Deafness, run by Institut Pasteur.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 31 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Correlation between neural recordings and IA models (time frame: Day 1). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Jul 2026.